Lantheus

Lantheus helps doctors find and treat heart disease and cancer using special medical imaging tools. These products create clear pictures of the body to help experts make better health decisions for their patients. The company focuses on using advanced technology to track and fight serious illnesses.

What Lantheus Makes

• Radiopharmaceutical Oncology: Imaging agents like PYLARIFY that find prostate cancer cells; uses PET (Positron Emission Tomography) scans to locate disease.
• Precision Diagnostics: Heart imaging tools like DEFINITY that help doctors see the heart clearly during ultrasound exams.
• Neurology Tools: Brain imaging products such as Neuraceq that help identify signs of Alzheimer’s disease in adults with memory loss.
• Digital Solutions: Artificial intelligence software that helps medical staff analyze bone scans and prostate cancer images more accurately.
• Manufacturing Services: Development and production help for other companies through the acquired Evergreen business facility.

Recent Strategic Moves

• Acquired Life Molecular Imaging Limited in July 2025 to expand brain imaging and international research capabilities.
• Purchased Evergreen Theragnostics, Inc. in April 2025 to add specialized manufacturing services and new drug discovery tools.
• Sold the SPECT (single-photon emission computerized tomography) business to SHINE Technologies in January 2026 to focus on higher-tech PET diagnostics.
• Gained global rights to several new assets from Radiopharm Theranostics Limited and Meilleur in 2024 to grow the medicine pipeline.

What Makes the Business Different

Lantheus maintains a broad network of manufacturing sites that allows for the rapid delivery of medical imaging products with short shelf lives across the United States. The company integrates artificial intelligence with traditional imaging to provide more precise data for cancer and brain disease monitoring.

Financial Performance by the Numbers

• Revenue reached $406.8 million in Q4 2025, representing a 4% increase from $391.1 million in Q4 2024.
• Net income rose to $54.1 million in Q4 2025, up significantly from a loss of $11.8 million in Q4 2024.
• Free cash flow was $81.4 million in Q4 2025, down 41.5% from $139 million in the previous year.
• Operating income hit $77.2 million in Q4 2025, down 32.2% from $113.9 million in Q4 2024.

The Evolution of Lantheus

Lantheus has shifted its focus from older diagnostic technologies to advanced PET imaging and targeted cancer therapies. Through major acquisitions in 2025, the company has broadened its reach into brain health and specialized medical manufacturing.